Latest news with #drugpipeline
Bloomberg
3 days ago
- Business
- Bloomberg
Merck KGaA Signs $2 Billion Neurology Drug Pact With Skyhawk
Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be valued at more than $2 billion as the German company seeks to bolster its drug pipeline. The work with Massachusetts-based Skyhawk will focus on the discovery of RNA-targeting small molecules for neurological conditions with high unmet medical need, according to a statement Monday. The deal value includes unspecified upfront and milestone payments, along with the potential for royalties on future sales.
Bloomberg
06-08-2025
- Business
- Bloomberg
Avidity Bio Climbs on Report of Novartis Takeover
Novartis AG is weighing a takeover of rare disease-focused biotech firm Avidity Biosciences Inc. in a bid to boost its drug pipeline, according to the Financial Times. The Swiss drugmaker has expressed interest in Avidity in recent weeks, the FT said, citing people familiar with the situation who weren't named. There's no guarantee a deal will be reached, they said.
Yahoo
03-08-2025
- Business
- Yahoo
Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer
We recently published . Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)'s shares have lost 18.3% year-to-date on the back of several factors, such as troubles in China and the expiration of its KEYTRUDA patents. Cramer's previous comments about the firm have praised the firm's deal with Verona, through which it will get access to a chronic pulmonary obstructive disease (COPD) treatment. The acquisition is important as investors have grown concerned about Merck & Co., Inc. (NYSE:MRK)'s drug pipeline and wondered whether future drugs will mimic KEYTRUDA's success. Cramer discussed these factors: 'Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you've got the KEYTRUDA, you know the patent cliff coming up. . .it's amazing, but they are talking about their animal division. When you're talking about your animal division you don't have enough [inaudible] to talk.' Later in the day, he commented on Merck & Co., Inc. (NYSE:MRK)'s earnings: 'What do we make of the numbers that we got from Merck this morning? The pharma titan reported what some thought was a mixed quarter. I actually liked it. Small revenue miss, paired with an 11-cent earnings beat. Stock got hit, finishing the day down nearly 2% although it was a lot lower at one point. While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
